Related Experiment Video
Updated: Mar 24, 2026
08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.9K
Cardiovascular Pharmacogenomics--Implications for Patients With CKD.
Larisa H Cavallari1, Darius L Mason1
1Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, FL; Division of Nephrology and Hypertension, Albany Medical College, Albany, NY; and Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY.
Advances in Chronic Kidney Disease
|March 17, 2016
Summary
Chronic kidney disease (CKD) increases cardiovascular disease (CVD) risk, necessitating pharmacogenomic approaches for personalized drug therapy. Tailoring treatments using genetic insights can improve patient outcomes and reduce adverse effects.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Nephrology
Background:
- Chronic kidney disease (CKD) is a significant independent risk factor for cardiovascular disease (CVD).
- Patients with CKD often require multiple cardiovascular medications, including antiplatelet, antihypertensive, anticoagulant, and lipid-lowering agents.
- Interpatient variability in drug response can lead to treatment failure or adverse drug effects in CVD patients.
Purpose of the Study:
- To explore the potential of pharmacogenomics in optimizing cardiovascular pharmacotherapy for patients with CKD.
- To review existing pharmacogenomic data for commonly prescribed cardiovascular drugs in CKD patients.
- To highlight the integration of genetic testing with clinical factors for personalized CVD drug therapy.
Main Methods:
- Review of existing literature on pharmacogenomics in cardiovascular drug therapy.
- Analysis of pharmacogenomic data for specific drug classes like warfarin, clopidogrel, statins, and beta-blockers.
- Examination of current guidelines for applying pharmacogenetic testing in clinical practice.
Main Results:
- Pharmacogenomics shows promise for optimizing cardiovascular drug therapy, though data in CKD patients are limited.
- Warfarin, clopidogrel, and statins have the most established pharmacogenomic evidence.
- Guidelines exist for using pharmacogenetics to guide warfarin dosing, antiplatelet selection, and statin-induced myopathy risk prediction.
Conclusions:
- Pharmacogenomic testing, alongside clinical factors, can personalize drug therapy for CVD patients, including those with CKD.
- Further research is needed to expand pharmacogenomic applications in CKD populations.
- Integrating genetic information holds potential to improve cardiovascular pharmacotherapy outcomes.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
108
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
01:27Pharmacogenetics of Drug Metabolism: Overview
106
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
106
01:29Pharmacogenetics and Pharmacogenomics: Overview
137
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
137
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
124
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
124
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
301
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
301